Cystic fibrosis since 1938
- PMID: 16126935
- DOI: 10.1164/rccm.200505-840OE
Cystic fibrosis since 1938
Abstract
Cystic fibrosis (CF) was distinguished from celiac disease in 1938. Then, it was a pathologic diagnosis, life expectancy was approximately 6 months, and the autosomal recessive disease was believed to arise from abnormal mucus plugging exocrine ducts. Death often occurred from lung infection. Discovery of the sweat electrolyte defect in 1953 and standardization of the sweat test in 1959 allowed identification of milder cases, and CF was no longer considered only a disorder of mucus. In 1955, establishment of centers with programs of aggressive, comprehensive care initiated striking improvement in longevity. The pillars of care established then (attention to nutrition, airway clearance, treatment of lung infection) remain today. In 1983, chloride transport was identified as the basic physiologic CF defect, accompanied by increased sodium reabsorption. In 1980, we learned that inflammation contributes independently to lung disease and constitutes an independent therapeutic target. In 1989, the discovery of the CF gene demonstrated the basic defect to be in a cAMP-regulated chloride channel. This afforded new diagnostic tests, opportunities for research, and prospects for using the gene as therapy. Since then, substantial advances in basic and clinical research catalyzed therapeutic improvements: median survival age now exceeds 30 years. The Cystic Fibrosis Foundation center network provides not only opportunity to conduct clinical trials but also means to disseminate new therapies. In the future, treatments directed at the basic defect can be expected, with concomitant improvements in morbidity and mortality.
Similar articles
-
Review of Cystic Fibrosis.Pediatr Ann. 2019 Apr 1;48(4):e154-e161. doi: 10.3928/19382359-20190327-01. Pediatr Ann. 2019. PMID: 30986316 Review.
-
Cystic fibrosis.Lancet. 2016 Nov 19;388(10059):2519-2531. doi: 10.1016/S0140-6736(16)00576-6. Epub 2016 Apr 29. Lancet. 2016. PMID: 27140670 Review.
-
New treatments targeting the basic defects in cystic fibrosis.Presse Med. 2017 Jun;46(6 Pt 2):e165-e175. doi: 10.1016/j.lpm.2017.01.024. Epub 2017 May 26. Presse Med. 2017. PMID: 28554723 Review.
-
Cystic fibrosis -- therapeutic challenge in cystic fibrosis children.Eur J Endocrinol. 2004 Aug;151 Suppl 1:S77-80. doi: 10.1530/eje.0.151s077. Eur J Endocrinol. 2004. PMID: 15339249 Review.
-
Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.Am J Respir Med. 2003;2(4):299-309. doi: 10.1007/BF03256658. Am J Respir Med. 2003. PMID: 14719996 Review.
Cited by
-
Association of cystic fibrosis transmembrane conductance regulator with epithelial sodium channel subunits carrying Liddle's syndrome mutations.Am J Physiol Lung Cell Mol Physiol. 2021 Aug 1;321(2):L308-L320. doi: 10.1152/ajplung.00298.2020. Epub 2021 May 26. Am J Physiol Lung Cell Mol Physiol. 2021. PMID: 34037494 Free PMC article.
-
Impact of KLF4 on Cell Proliferation and Epithelial Differentiation in the Context of Cystic Fibrosis.Int J Mol Sci. 2020 Sep 14;21(18):6717. doi: 10.3390/ijms21186717. Int J Mol Sci. 2020. PMID: 32937756 Free PMC article.
-
PDE5 Inhibitors as Potential Tools in the Treatment of Cystic Fibrosis.Front Pharmacol. 2012 Sep 18;3:167. doi: 10.3389/fphar.2012.00167. eCollection 2012. Front Pharmacol. 2012. PMID: 23024633 Free PMC article.
-
Mucins and CFTR: Their Close Relationship.Int J Mol Sci. 2022 Sep 6;23(18):10232. doi: 10.3390/ijms231810232. Int J Mol Sci. 2022. PMID: 36142171 Free PMC article. Review.
-
Brazilian consensus on non-cystic fibrosis bronchiectasis.J Bras Pneumol. 2019 Aug 12;45(4):e20190122. doi: 10.1590/1806-3713/e20190122. J Bras Pneumol. 2019. PMID: 31411280 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical